RNA Avidity Biosciences Inc Projected Price to Earnings
Avidity Biosciences (RNA) develops innovative RNA-based therapeutics in US laboratories, targeting the genetics of diseases. The company's estimated forward P/E on this GURU.Markets platform chart confirms this stability, where 0.00 characterizes this valuation parameter. Protection against replication is ensured by elite patents on conjugates, while a sophisticated infrastructure and a unique intellectual property portfolio support high business margins.
Analytical breakdowns for Avidity Corp (RNA)
- stock quotes and analyst forecast:
- market capitalization data:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Avidity Biosciences|RNA - Long-Term Debt to Equity|Short-Term Debt to Capital Avidity Biosciences|RNA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Avidity Biosciences Inc|RNA - Long-Term Debt|Company Short-Term Debt Avidity Biosciences|Quick Ratio aviditybiosciences.com
- financial results and valuation multiples details:
RNA - Net Income|Projected Future Earnings Avidity Biosciences|RNA - Business Payback Period|Forward P/E Multiple Avidity|RNA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avidity Biosciences Inc|RNA - Operating profit before amortization|Net earnings per share (EPS TTM) Avidity Biosciences|RNA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth aviditybiosciences.com|RNA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Avidity Biosciences
Basic company analysis:RNA Avidity Biosciences, Inc.
Fundamental risks for Avidity Biosciences (RNA) are assessed through the ratio of market capitalization to projected net income, which allows for the determination of the asset's fair value. By analyzing the company's expected P/E ratio, an investor compares current development costs for unique RNA drugs with the potential for monopoly pricing power upon successful clinical trials, identifying entry points with an optimal balance of price and future returns.
Competitors of Avidity Biosciences (RNA)
Forward P/E Multiple TEM|Market Cap to Projected Earnings Qiagen NV|Ionis Pharma - Projected Price to Earnings|Market Cap to Future Earnings Ratio RGEN (Repligen Inc.)|CRSP: Projected Price to Earnings|Projected Price to Earnings Ratio genedx.com|RARE (Ultragenyx) - Projected Price to Earnings|Beam Therapeutics Inc - Future Price to Earnings Multiple|SRPT (Sarepta Therapeutics Inc) - Forward P/E Multiple|Future Price to Earnings TWST|Forward P/E Multiple TXG|Market Cap to Projected Earnings intelliatx.com|Future Price to Earnings Stoke Therapeutics, Inc. STOK|BioLife Solutions Inc (BLFS) - Projected Price to Earnings Ratio|WVE - Future Price to Earnings|Market Cap to Projected Earnings Maze Therapeutics Corp MAZE|SION: Forward P/E Multiple|Projected Price to Earnings primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - Forward P/E Multiple|uniQure NV (QURE) - Market Cap to Projected Earnings|Forward P/E Multiple MGTX|RGNX - Projected Price to Earnings Ratio|Future Price to Earnings Solid Biosciences Inc. SLDB|OCGN: Price to Future Earnings Ratio|PacBio - Forward P/E Multiple|Benitec Biopharma Inc (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|Projected Price to Earnings Ratio Rocket Corp (RCKT)|Future Price to Earnings 4D Molecular Therapeutics|Lexeo (LXEO) - Market Cap to Projected Earnings|Future Price to Earnings Korro Bio, Inc. (KRRO)|EDIT (Editas Medicine Inc) - Future Price to Earnings Multiple|Future Price to Earnings Silence Therapeutics Inc. SLN|PRQR: Price to Future Earnings Ratio|Codexis Bio - Forward P/E Multiple|SGMO - Forward P/E Multiple|NAUT: Forward P/E Multiple|Price to Future Earnings Ratio MGX|Future Price to Earnings Precision BioSciences, Inc.|Price to Future Earnings Ratio GBIO (Generation Bio Corp)|Forward P/E Multiple BOLD|Forward P/E Multiple exicuretx.com (XCUR)|Forward P/E Multiple IMNN (Imunon)|Forward P/E Multiple Phio Pharmaceuticals Corp PHIO|MBIO: Projected Price to Earnings|RNAZ: Future Price to Earnings|BNGO: Forward P/E Multiple|APDN - Market Cap to Projected Earnings|BLUE (bluebird bio) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise)|Forward P/E Multiple OMGA|Market Cap to Projected Earnings Singular Genomics Corp|Regulus Therapeutics - Projected Price to Earnings|Market Cap to Future Earnings Ratio SYRS (syros.com)|TBIO: Projected Price to Earnings|Projected Price to Earnings Ratio TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Projected Price to Earnings
